UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



____________________________

FORM 10-Q


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended March 31, September 30, 2013


Commission File Number 001-31932

_______________________

001-31932



CATASYS, INC.

(Exact name of registrant as specified in its charter)



_______________________

Delaware

88-0464853

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)


11150 Santa Monica Boulevard, Suite 1500, Los Angeles, California 90025

(Address of principal executive offices, including zip code)


(310) 444-4300

(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.


Yes þ          No o

Yes☑          No☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    


Yes þ          No o

Yes☑          No☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definitions of ‘‘accelerated“accelerated filer,” “large accelerated filer,’’ and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o      Accelerated filer  o      Non-accelerated filer  o      Smaller reporting company  þ

Large accelerated filer ☐

Accelerated filer  ☐

Non-accelerated filer  ☐

Smaller reporting company  ☑

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).


Yes o            No þ

Yes☐            No☑

As of May 14,November 13, 2013, there were 14,274,016 sharestherewere 18,835,571shares of registrant's common stock, $0.0001 par value, outstanding.

 

1

TABLE OF CONTENTS



PART I - FINANCIAL INFORMATION

3

    
 

ITEM 1. Financial Statements

3

Condensed Consolidated Balance Sheets as of September 30, 2013(unaudited) and December 31, 2012

3
    
  

Condensed Consolidated Balance Sheets asStatements of March 31,Operations for theThree and Nine Months Ended September 30, 2013 and December 31, 2012

(unaudited)

3

4

    
  

Condensed Consolidated Statements of OperationsCash Flows for theThree and Nine Months Ended March 31,September 30, 2013 and 2012

(unaudited)

4

5

    
  

Notes to Condensed Consolidated Financial Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012

5

6

    
 

ITEM 2. Management's Discussion and Analysis of FinancialCondition and Results of Operations

Notes to Condensed Consolidated Financial Statements19
6

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

26

    
 

ITEM 2. Management's Discussion4. Controls and Analysis of Financial Condition and Results of Operations

Procedures

18

26

PART II – OTHER INFORMATION

28

    
 ITEM 3. Quantitative and Qualitative Disclosures About Market Risk24
ITEM 4. Controls and Procedures24
PART II – OTHER INFORMATION25

ITEM 1. Legal Proceedings

25

28

   
 

ITEM 1A. Risk Factors

25

28

   
 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

26

28

   
 

ITEM 3. Defaults Upon Senior Securities

26

29

   
 

ITEM 4. Mine Safety Disclosures

26

29

   
 

ITEM 5. Other Information

26

29

   
 

ITEM 6. Exhibits

26

29

In this report, except as otherwise stated or the context otherwise requires, the terms “we,” “us” or “our” refer to Catasys, Inc. and our wholly-owned subsidiaries. Our common stock, par value $0.0001 per share, is referred to as “common stock.”

 

2

PART I - FINANCIAL INFORMATION


Item 1.     Financial Statements


CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


(In thousands, except for number of shares) 
(unaudited)
March 31,
2013
  
December 31,
2012
 
ASSETS      
Current assets      
Cash and cash equivalents $1,608  $3,153 
Receivables, net of allowance for doubtful accounts of $0 and $0, respectively
  76   69 
Receivables from related party  205   173 
Prepaids and other current assets  209   227 
Total current assets  2,098   3,622 
Long-term assets        
Property and equipment, net of accumulated depreciation of $4,677 and $4,668, respectively
  48   59 
Intangible assets, net of accumulated amortization of $928 and $892, respectively
  1,012   1,048 
Deposits and other assets  175   205 
Total Assets $3,333  $4,934 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
Current liabilities        
Accounts payable $1,648  $1,642 
Accrued compensation and benefits  1,113   958 
Deferred revenue  316   278 
Other accrued liabilities  998   1,120 
Total current liabilities  4,075   3,998 
Long-term liabilities        
Deferred rent and other long-term liabilities  -   18 
Capital leases  15   18 
Warrant liabilities  10,169   14,658 
Total Liabilities  14,259   18,692 
         
Stockholders' deficit        
Preferred stock, $0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding
  -   - 
Common stock, $0.0001 par value; 500,000,000 and 2,000,000,000 shares authorized at March 31, 2013 and December 31, 2012, respectively; 12,081,187 and 12,022,853 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively
  12   12 
Additional paid-in-capital  208,984   208,765 
Accumulated deficit  (219,922)  (222,535)
Total Stockholders' deficit  (10,926)  (13,758)
Total Liabilities and Stockholders' deficit $3,333  $4,934 

(In thousands, except for number of shares)

 

(unaudited)

September 30,

2013

  

December 31,

2012

 
         

ASSETS

        

Current assets

        

Cash and cash equivalents

 $422  $3,153 

Receivables, net of allowance for doubtful accountsof $9 and $0, respectively

  113   69 

Receivables from related party

  269   173 

Prepaids and other current assets

  119   227 

Total current assets

  923   3,622 

Long-term assets

        

Property and equipment, net of accumulated depreciationof $4,501 and $4,668, respectively

  44   59 

Intangible assets, net of accumulated amortization of$995 and $892, respectively

  945   1,048 

Deposits and other assets

  175   205 

Total Assets

 $2,087  $4,934 
         

LIABILITIES AND STOCKHOLDERS' DEFICIT

        

Current liabilities

        

Accounts payable

 $1,268  $1,642 

Accrued compensation and benefits

  1,217   958 

Deferred revenue

  667   278 

Other accrued liabilities

  1,314   1,120 

Total current liabilities

  4,466   3,998 

Long-term liabilities

        

Deferred rent and other long-term liabilities

  -   18 

Capital leases

  18   18 

Warrant liabilities

  14,196   14,658 

Total Liabilities

  18,680   18,692 
         

Stockholders' deficit

        

Preferred stock, $0.0001 par value; 50,000,000 shares authorized;no shares issued and outstanding

  -   - 

Common stock, $0.0001 par value; 500,000,000 shares authorized;14,285,569 and 12,022,853 shares issued and outstandingat September 30, 2013 and December 31, 2012, respectively

  2   1 

Additional paid-in-capital

  209,121   208,776 

Accumulated deficit

  (225,716)  (222,535)

Total Stockholders' deficit

  (16,593)  (13,758)

Total Liabilities and Stockholders' Deficit

 $2,087  $4,934 

* The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split thatsplitthat occurred on May 6, 2013.


See accompanying notes to the financial statements.

 

3


CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share amounts) 
Three Months Ended
March 31,
 
  2013  2012 
Revenues      
Healthcare services revenues $99  $40 
License and management services revenues  36   53 
Total revenues $135  $93 
         
Operating expenses        
Cost of healthcare services $204  $204 
General and administrative  1,629   2,570 
Impairment losses  -   34 
Depreciation and amortization  47   81 
Total operating expenses $1,880  $2,889 
         
Loss from operations $(1,745) $(2,796)
         
Interest expense  -   (621)
Change in fair value of warrant liability  4,360   37 
Income/(Loss) from operations before provision for income taxes $2,615  $(3,380)
Provision for income taxes  2   (7)
Net Income/(Loss) $2,613  $(3,373)
         
Basic and diluted net income (loss) per share:*        
Basic net income (loss) per share* $0.22  $(0.99)
         
Basic weighted number of shares outstanding*  12,057   3,390 
         
Diluted net income (loss) per share* $0.16  $(0.99)
         
Diluted weighted number of shares outstanding*  16,562   3,390 

(In thousands, except per share amounts)

 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2013

  

2012

  

2013

  

2012

 

Revenues

                

Healthcare services revenues

 $109  $100  $315  $226 

License and management services revenues

  21   40   83   136 

Total revenues

  130   140   398   362 
                 

Operating expenses

                

Cost of services

  221   197   628   618 

General and administrative

  1,415   1,946   4,651   6,629 

Impairment losses

  -   -   -   189 

Depreciation and amortization

  42   69   131   227 

Total operating expenses

  1,678   2,212   5,410   7,663 
                 

Loss from operations

  (1,548)  (2,072)  (5,012)  (7,301)
                 

Interest and other income

  -   -   -   - 

Interest expense

  (1)  (1)  (771)  (2,697)

Change in fair value of warrant liability

  2,231   1,818   2,607   4,127 

Income/(Loss) from operations before provision for income taxes

  682   (255)  (3,176)  (5,871)

Provision for income taxes

  2   2   5   18 

Net Income/(Loss)

 $680  $(257) $(3,181) $(5,889)
                 

Basic and diluted net income (loss) per share:*

                

Basic net income (loss) per share*

 $0.05  $(0.04) $(0.24) $(1.23)
                 

Basic weighted number of shares outstanding*

  14,286   5,908   13,429   4,802 
                 

Diluted net income (loss) per share*

 $0.04  $(0.04) $(0.24) $(1.23)
                 

Diluted weighted number of shares outstanding*

  19,364   5,908   13,429   4,802 

* The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split thatsplitthat occurred on May 6, 2013.


See accompanying notes to the financial statements.

 

4

CATASYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(unaudited)

(In thousands) 
Three Months Ended
March 31,
 
  2013  2012 
Operating activities:      
Net income/(loss) $2,613  $(3,373)
Adjustments to reconcile net income/(loss) to net cash used in operating activities:        
Depreciation and amortization  47   81 
Amortization of debt discount and issuance costs included in interest expense  -   611 
Provision for doubtful accounts  -   (4)
Share-based compensation expense  68   821 
Fair value adjustment on warrant liability  (4,360)  (37)
Impairment losses  -   34 
Changes in current assets and liabilities:        
Receivables  (39)  30 
Prepaids and other current assets  47   23 
Deferred revenue  38   102 
Accounts payable and other accrued liabilities  21   275 
Net cash used in operating activities $(1,565) $(1,437)
         
Investing activities:        
Deposits and other assets $-  $(16)
Net cash used in investing activities $-  $(16)
         
Financing activities:        
Proceeds from bridge loan $-  $775 
Proceeds from the exercise of warrants  23   - 
Capital lease obligations  (3)  (2)
Net cash provided by financing activities $20  $773 
         
Net decrease in cash and cash equivalents $(1,545) $(680)
Cash and cash equivalents at beginning of period  3,153   771 
Cash and cash equivalents at end of period $1,608  $91 
         
Supplemental disclosure of cash paid        
Income taxes $5  $3 
Supplemental disclosure of non-cash activity        
Common stock issued for services $-  $102 
Common stock issued for exercise of warrants $129  $- 
Beneficial conversion feature related to financing $-  $230 

(In thousands)

 

Nine Months Ended

September 30,

 
  

2013

  

2012

 

Operating activities:

        

Net loss

 $(3,181) $(5,889)

Adjustments to reconcile net income (loss) to net cash used in operating activities:

        

Depreciation and amortization

  131   227 

Amortization of debt discount and issuance costs included in interest expense

  769   2,681 

Provision for doubtful accounts

  9   (4)

Share-based compensation expense

  165   1,963 

Fair value adjustment on warrant liability

  (2,607)  (4,127)

Impairment losses

  -   189 

(Gain) or loss on disposition of assets

  -   (1)

Changes in current assets and liabilities:

        

Receivables

  (149)  (40)

Prepaids and other current assets

  137   24 

Deferred revenue

  389   221 

Accounts payable and other accrued liabilities

  57   229 

Net cash used in operating activities

 $(4,280) $(4,527)
         

Investing activities:

        

Deposits and other assets

 $-  $(3)

Net cash used in investing activities

 $-  $(3)
         

Financing activities:

        

Proceeds from the issuance of common stock and warrants

 $1,535  $4,287 

Proceeds from the exercise of warrants

  23   - 

Proceeds from financing notes

  -   975 

Capital lease obligations

  (9)  (7)

Net cash provided by financing activities

 $1,549  $5,255 
         

Net increase (decrease) in cash and cash equivalents

 $(2,731) $725 

Cash and cash equivalents at beginning of period

  3,153   771 

Cash and cash equivalents at end of period

 $422  $1,496 
         

Supplemental disclosure of cash paid

        

Income taxes

 $37  $93 

Supplemental disclosure of non-cash activity

        

Common stock issued for converson of debt

 $-  $975 

Common stock issued for services

 $-  $309 

Common stock issued for exercise of warrants

 $156  $- 

Beneficial conversion feature related to financing

 $-  $253 

Property and equipment acquired through capital leasesand other financing

 $13  $31 

See accompanying notes to the financial statements.

 

5

Catasys, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)


Note 1. Basis of Consolidation, Presentation and Going Concern


The accompanying unaudited interim condensed consolidated financial statements for Catasys, Inc. and our subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included.  Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in our most recent Annual Report on Form 10-K, from which the December 31, 2012 balance sheet hashave been derived.


Our financial statements have been prepared on the basis that we will continue as a going concern. At March 31,September 30, 2013, cash and cash equivalents amounted to $1.6 million$422,000 and we had a working capital deficit of approximately $2.0$3.5 million. On April 10,In October 2013, we closed on a financing of approximately $1.5$2.6 million. We have incurred significant operating losses and negative cash flows from operations since our inception. During the threenine months ended March 31,September 30, 2013, our cash used in operating activities amounted $1.6to $4.3 million. We anticipate that we could continue to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of March 31,September 30, 2013, these conditions raised substantial doubt as to our ability to continue as a going concern.

Our ability to fund our ongoing operations and continue as a going concern is dependent on our increasing fees from existing contracts and signing and generating fees from existingnew and newexisting contracts for our Catasys managed care programs and the success of management’s plans to increase revenue and continue to control expenses. We are operatingoperated our programs in Kansas, Louisiana, Massachusetts, and Oklahoma and Massachusetts.  during the third quarter of 2013. In March 2013, we signed an agreementtwo agreements with a national health planplans to provide services to their members in New Jersey whichand Ohio, West Virginia, Kentucky, and Indiana, respectively. We commenced enrollment for Humana, one of the national insurers in the fourth quarter of 2013, and we expect to continue to expand enrollment with Humana and commence enrollment with the other national insurer during the secondfourth quarter of 2013. WeDuring the nine months ending September 30, 2013, we have begun to generategenerated increased fees from theour launched programs we increased fees during the first quarter of 2013 over the same period in the prior year, and we expect to continue to increase enrollment and fees from our programs throughout this year.year both from existing programs and the contracts we signed in 2013. In addition, we are involved in contract negotiations with other potential customers that we expect to sign in the fourth quarter. However, there can be no assurance that we will generate such fees. In addition, we have continuedfees or sign additional contracts. We continue to seeklook for areas to reduce our operating expenses.


 We and our Chief Executive Officer are party to a litigation in which the plaintiffs assert causes of action for conversion, a request for an order to set aside fraudulent conveyance and breach of contract. A judgment in our favor was entered by the court in November 2012, however the plaintiff has appealed the judgment. While we believe the plaintiffs’ claims are without merit and we intend to continue to vigorously defend the case, there can be no assurance that the litigation will be resolved in our favor. If this case is decided against us or our Chief Executive Officer, it may cause us to pay substantial damages, and other related fees. Regardless of whether this litigation is resolved in our favor, any lawsuit to which we are a party will likely be expensive and time consuming to defend or resolve. Costs of defense and any damages resulting from litigation, a ruling against us or a settlement of the litigation could have a significant negative impact on our liquidity, including our cash flows.


Based on the provisions of our management services agreement (“MSA”) between us and our managed professional medical corporation, we have determined that our managed professional medical corporation constitutes a variable interest entity, and that we are the primary beneficiary as defined in Financial Accounting Standards Board (“FASB”) Interpretation No. 46R “Consolidation of Variable Interest Entities, an Interpretation of Accounting Research Bulletin No. 51” (“FIN 46R”).  Accordingly, we are required to consolidate the revenue and expenses of our managed professional medical corporation. See Management ServiceServices Agreement heading under Note 2, Summary of Significant Accounting Policies, for more discussion.


All intercompany transactions and balances have been eliminated in consolidation.

6


Note 2. Summary of Significant Accounting Policies


Revenue Recognition


Healthcare Services


        Our Catasys contracts are generally designed to provide revenues to us on a monthly basis based on enrolled members. To the extent our contracts may include a minimum performance guarantee, we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates that are not subject to the performance guarantees, we recognize the case rate ratably over twelve months.


License and Management Services


Our license and management services revenues are primarily derived from licensing our PROMETA Treatment Program and providing administrative services to hospitals, treatment facilities and other healthcare providers, and from revenues generated by our managed treatment center.  We record revenues earned based on the terms of our licensing and management contracts, which require the use of judgment, including the assessment of the collectability of receivables. Licensing agreements typically provide for a fixed fee on a per-patient basis, payable to us following the providers’ commencement of the use of our program to treat patients.  For revenue recognition purposes, we treat the program licensing and related administrative services as one unit of accounting.  We record the fees owed to us under the terms of the agreements at the time we have performed substantially all required services for each use of our program, which for our license agreements is in the period in which the provider begins using the program for medically directed and supervised treatment of a patient. 


The revenues of our managed treatment center, which we include in our condensed consolidated financial statements, and which are derived from charging fees directly to patients for treatment and are recorded when services are provided. Revenues from patients treated with our proprietary treatment program are recorded based on the number of days of treatment completed during the period as a percentage of the total number treatment days for the treatment program.

Revenues for other services are recognized when services are rendered.

Cost of Services


Healthcare Services


Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Healthcare services cost of services is recognized in the period in which an eligible member receives services. Our Catasys subsidiary contractsWe contract with various healthcare providers, includingdoctors and licensed behavioral healthcare professionals, on a contracted ratefee-for-services basis. We determine that a member has received services when we receive a claim or in the absence of a claim, by utilizing member data recorded in the OneOnTrakTM database within the contracted timeframe, with all required billing elements correctly completed by the service provider.


License and Management Services


Cost of license and management services representprimarily represents direct costs associated with providing care to patients that are incurred in connection with licensing our treatment programs and providing administrative services in accordance with the various technology license and services agreements, and are associated directly with the revenue that we recognize. Consistent with our revenue recognition policy, the costs associated with providing these services are recognized when services have been rendered, which for our license agreements is in the period in which patient treatment commences, and for our managed treatment center iscenter. Costs are recognized in the periods in which medical treatment is provided. Such costs include, royalties,but are not limited to, direct labor costs, medical supplies and medications.


Cash Equivalents and Concentration of Credit Risk


We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents, and accounts receivable. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed FDICFederal Deposit Insurance Corporation (“FDIC”) insured limits.

7


For the threenine months ended March 31,September 30, 2013, one customer accounted for approximately 60%64% of revenues and three customers accounted for approximately 93%91% of accounts receivable.


Basic and Diluted Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period.


Common equivalent shares, consisting of 11,593,5985,077,669 incremental common shares as of March 31,for the three months ended September 30, 2013, issuable upon the exercise of stock options and warrants have been included in the diluted earnings per share calculation.


Common equivalent These shares consisting of 2,895,718 incremental common shares as of March 31,have not been included for the three and nine month ended September 30, 2012 issuable uponor the exercise of stock options and warrants have been excluded from the diluted earnings per share calculationnine months ended September 2013 because their effect is anti-dilutive.

  
Three Months Ended
March 31
 
(in thousands, except per share amounts) 2013  2012 
       
Numerator      
       
Net income (loss) $2,613  $(3,373)
         
Denominator        
         
Weighted-average common shares outstanding  12,057   3,390 
         
Shares used in calculation - basic  12,057   3,390 
         
Stock options and warrants  4,505   - 
         
Shares used in calculation - diluted  16,562   3,390 
         
Net income (loss) per share        
         
Basic $0.22  $(0.99)
         
Diluted $0.16  $(0.99)

  

Three Months Ended

September 30

  

Nine Months Ended

September 30

 

(in thousands, except per share amounts)

 

2013

  

2012

  

2013

  

2012

 
                 

Numerator

                
                 

Net income (loss)

 $680  $(257) $(3,181) $(5,889)
                 

Denominator

                
                 

Weighted-average common shares outstanding

  14,286   5,908   13,429   4,802 
                 

Shares used in calculation - basic

  14,286   5,908   13,429   4,802 
                 

Shares issuable for stock options and warrants

  5,078   -   -   - 
                 

Shares used in calculation - diluted

  19,364   5,908   13,429   4,802 
                 

Net income (loss) per share

                
                 

Basic

 $0.05  $(0.04) $(0.24) $(1.23)
                 

Diluted

 $0.04  $(0.04) $(0.24) $(1.23)

Share-Based Compensation


Our 2010 Stock Incentive Plan, as amended, (the “Plan”), provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At March 31,September 30, 2013, we had 487,589482,177 vested and unvested optionsshares outstanding and 1,280,1751,285,586 shares available for future awards.

8


Share-based compensation expense attributable to continuing operations was $68,000amounted to $48,000 and $821,000$165,000 for the three and nine months ended March 31,September 30, 2013, compared with $371,000 and 2012, respectively.$2.0 million, respectively, for the same periods in 2012.


Stock Options – Employees and Directors


We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-ScholesBlack Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the condensed consolidated statements of operations subsequent to January 1, 2006. We account for share-based awards to employees and directors using the intrinsic value method under previous FASB rules, allowable prior to January 1, 2006. Under the intrinsic value method, no share-based compensation expense had been recognized in our consolidated statements of operations for awards to employees and directors because the exercise price of our stock options equaled the fair market value of the underlying stock at the date of grant.


Share-based compensation expense recognized for employees and directors for the three and nine months ended March 31,September 30, 2013, and 2012, amounted towas $47,000 and $680,000,$141,000, compared with $273,000 and $1.6 million for the same periods in 2012, respectively.


Share-based compensation expense recognized in our condensed consolidated statements of operations for the three and nine months ended March 31,September 30, 2013 and 2012, includes compensation expense for share-based payment awards granted prior to, but not yet vested, as of January 1, 2006, based on the grant date fair value estimated in accordance with the pro-forma provisions of Statement of Financial Accounting Standards (“SFAS”) 123, and for the share-based payment awards granted subsequent to January 1, 2006 based on the grant date fair value estimated in accordance with the provisions of the Accounting Standards Codification (“ASC”) 718. For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our condensed consolidated statements of operations for the three and nine months ended March 31,September 30, 2013 and 2012, is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.


During the three and nine months ended March 31,September 30, 2013, there were no options granted to employees, compared with 0 and 5,00050,000 options granted to employees at the weighted average per share exercise price of $4.40 granted during$0.00 and $0.44, for the same periodperiods in 2012.2012, respectively. All of the options were issued at the fair market value of our common stock on the date of grant. Employee and director stock option activity for the three and nine months ended March 31,September 30, 2013 are as follows:

  

Shares

  

Weighted Avg.

Exercise Price

 

Balance December 31, 2012

  486,000  $26.46 
         

Granted

  -  $- 

Canceled

  (20,000) $33.72 
         

Balance March 31, 2013

  466,000  $22.73 
         

Granted

  -  $- 

Canceled

  (1,000) $39.37 
         

Balance June 30, 2013

  465,000  $22.69 
         

Granted

  -  $- 

Canceled

  (4,000) $379.44 
         

Balance September 30, 2013

  461,000  $19.59 
 

 

  Shares  
Weighted Avg.
Exercise Price
 
Balance December 31, 2012  486,000  $26.46 
         
Granted  -  $- 
Cancelled  (20,000) $33.72 
         
Balance March 31, 2013  466,000  $22.73 

The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three and nine months ended March 31,September 30, 2013 and 2012, reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin (“SAB”) No. 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.


As of March 31,September 30, 2013, there was $186,005$92,000 of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 1.440.94 years.


Stock Options and Warrants – Non-employees


We account for the issuance of options and warrants for services from non-employees for services by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model’s calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

9


For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.


There were no options issued as compensation for consulting servicesto non-employees for the three and nine months ended March 31,September 30, 2013 and 2012, respectively. For the three months ended March 31, 2013 and 2012, share-basedShare-based compensation expense relating to stock options and warrants recognized for non-employees amounted to $20,000$1,000 and $17,000,$23,000 for the three and nine months ended September 30, 2013, and $61,000 and $81,000 for the three and nine months ended September 30, 2012, respectively.


Non-employee stock option activity for the three and nine months ended March 31,September 30, 2013, are as follows:

  

Shares

  

Weighted Avg.

Exercise Price

 

Balance December 31, 2012

  22,000  $48.97 
         

Canceled

  (1,000) $1,953.03 
         

Balance March 31, 2013

  21,000  $45.72 
         

Canceled

  -  $- 
         

Balance June 30, 2013

  21,000  $45.72 
         

Canceled

  -  $- 
         

Balance September 30, 2013

  21,000  $28.40 
 


  Shares  
Weighted Avg.
Exercise Price
 
Balance December 31, 2012  22,000  $48.97 
         
Cancelled  (1,000) $1,953.03 
         
Balance March 31, 2013  21,000  $45.72 

Common Stock


In April 2013, we entered into securities purchase agreements (the “April Agreements”) with several investors, including Crede CG II, LLC (“Crede”), an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus, LLC (“Shamus”), an affiliate of the Company, relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock and warrants (the “April Warrants”) to purchase an aggregate of 2,192,857 shares of common stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1.5 million (the “April Offering”). The April Agreements provide that in the event that we effectuate a reverse stock split of our common stock within 24 months of the closing date of the April Offering (the “Reverse Split”) and the volume weighted average price (“VWAP”) of the common stock during the 20 trading days following the effective date of the Reverse Split (the “VWAP Period”) declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue additional shares of common stock (the “Adjustment Shares”). We effectuated a reverse split on May 6, 2013, and no Adjustment Shares were issued.

There were no shares of common stock issued in exchange for various services or settlement of claims during the three and nine months ended March 31,September 30, 2013, or 2012.compared with 0 and 312,500 valued at $0 and $72,000, for the same period in 2012, respectively. The costs associated with shares issued for services are being amortized to share-based compensation expense on a straight-line basis over the related service periods. For the three and nine months ended March 31,September 30, 2013, and 2012, share-based compensation expense relating to all common stock issued for consulting services was $1,000 and $121,000,$23,000 compared with $61,000 and $81,000, for the same periods in 2012, respectively.


Income Taxes


The Company has

We have recorded a full valuation allowance against itsour otherwise recognizable deferred tax assets as of March 31,September 30, 2013.  As such, the Company haswe have not recorded a provision for income tax for the period ended March 31,September 30, 2013.  The Company utilizesWe utilize the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. In determining the need for valuation allowances the Company considerswe consider projected future taxable income and the availability of tax planning strategies.  After evaluating all positive and negative historical and perspective evidences, management has determined it is more likely than not that the Company'sour deferred tax assets will not be recognized. 

The Company assesses itsrealized. 

We assess our income tax positions and recordsrecord tax benefits for all years subject to examination based upon the Company’sour evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, the Company haswe have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.  Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended March 31,September 30, 2013 should be recognized.

10

realized.   

Fair Value Measurements


Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the

circumstances (unobservable outputs)inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1)I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:



Level Input:

 

Input Definition:

Level I

 

Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Level II

 

Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.

Level III

 

Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.


The following table summarizes fair value measurements by level at March 31,September 30, 2013 for assets and liabilities measured at fair value:


  2013 
(Dollars in thousands) Level I  Level II  Level III  Total 
Certificates of deposit $175  $-  $-  $175 
Total assets $175  $-  $-  $175 
                 
Warrant liabilities $-  $-  $10,169  $10,169 
Total liabilities $-  $-  $10,169  $10,169 

   

2013

 
                 

(in thousands)

                
  

Level I

  

Level II

  

Level III

  

Total

 

Certificates of deposit

 $175  $-  $-  $175 

Total assets

 $175  $-  $-  $175 
                 

Warrant liabilities

 $-  $-  $14,196  $14,196 

Total liabilities

 $-  $-  $14,196  $14,196 
 

Financial instruments classified as Level III in the fair value hierarchy as of March 31,September 30, 2013, represent our liabilities measured at market value on a recurring basis which include warrant liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities are being marked to marketmarked-to-market each quarter-end until they are completely settled. The warrants are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. SeeWarrant Liabilities below.


The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three and nine months ended March 31,September 30, 2013:

(Dollars in thousands)

 

Level III

Warrant

Liabilities

 

Balance as of December 31, 2012

 $14,658 

Reclassification to equity

  (129)

Change in fair value

  (4,360)

Net realized gains (losses)

  - 

Balance as of March 31, 2013

 $10,169 

Reclassification to equity

  (27)

Change in fair value

  3,985 

Net purchases (sales)

  2,301 

Net realized gains (losses)

  - 

Balance as of June 30, 2013

 $16,428 

Reclassification to equity

  - 

Change in fair value

  (2,232)

Net purchases (sales)

  - 

Net unrealized gains (losses)

  - 

Balance as of September 30, 2013

 $14,196 
 


(Dollars in thousands) 
Level III
Warrant
Liabilities
 
Balance as of December 31, 2012 $14,658 
Reclassification to equity  (129)
Change in fair value  (4,360)
Balance as of March 31, 2013 $10,169 

11

Intangible Assets

As of March 31,September 30, 2013, the gross and net carrying amounts of intangible assets that are subject to amortization are as follows:


(In thousands) 
Gross
Carrying
Amount
  
Accumulated
Amortization
 
Net
Balance
 
Amortization
Period
(in years)
 
Intellectual property $1,940  $(928) $1,012   8 

(In thousands)

 

Gross

Carrying

Amount

  

Accumulated

Amortization

  

Net

Balance

  

Amortization

Period

(in years)

 

Intellectual property

 $1,940  $(995) $945   8 

During the three and nine months ended March 31,September 30, 2013, we did not acquire any new intangible assets and at March 31,September 30, 2013, all of our intangible assets consisted of intellectual property, which is not subject to renewal or extension. As of March 31, 2013, weWe had no intangible impairment. As of March 31,impairment for the three and nine months ended September 30, 2013. We had no intangible impairment for the three months ended September 30, 2012 we determined thatand $189,000 for the remaining lives of certain intangibles exceeded their economic useful lives and therefore accelerated amortization and recorded an impairment amounting of $34,000.


nine months ended September 30, 2012.

Additionally, it is important to note that our overall business model, business operations and future prospects of our business have not changed materially since we performed the reviews and analysis noted above, with the exception of the timing, and annualized amounts of expected revenue.


Estimated remaining amortization expense for intangible assets for the current year and each of the next five years ending December 31 is as follows:


(In thousands) 
Year Amount 
2013 $108 
2014 $144 
2015 $144 
2016 $144 
2017 $144 

(In thousands)

    

Year

 

Amount

 

2013(3 months)

 $33 

2014

 $132 

2015

 $132 

2016

 $132 

2017

 $132 
 

Property and Equipment


Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.


Variable Interest Entities


Generally, an entity is defined as a Variable Interest Entity (“VIE”) under current accounting rules if it has (a) equity that is insufficient to permit the entity to finance its activities without additional subordinated financial support from other parties, or (b) equity investors that cannot make significant decisions about the entity’s operations, or that do not absorb the expected losses or receive the expected returns of the entity. When determining whether an entity that is a business qualifies as a VIE, we also consider whether (i) we participated significantly in the design of the entity, (ii) we provided more than half of the total financial support to the entity, and (iii) substantially all of the activities of the VIE either involve us or are conducted on our behalf. A VIE is consolidated by its primary beneficiary, which is the party that absorbs or receives a majority of the entity’s expected losses or expected residual returns.


As discussed under the heading Management Services Agreementbelow, we have an MSA with a managed medical corporation. Under this MSA, the equity owner of the affiliated medical group has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We participate significantly in the design of this MSA. We also agree to provide working capital loans to allow for the medical group to pay for its obligations. Substantially all of the activities of this managed medical corporation either involve us or are conducted for our benefit, as evidenced by the factsfact that (i) the operations of the managed medical corporation are conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the respective medical group. Payment of our management fee is subordinate to payments of the obligations of the medical group, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated medical group or other third party. Creditors of the managed medical corporation do not have recourse to our general credit.

 

12


Based on the design and provisions of this MSA and the working capital loans provided to the medical group, we have determined that the managed medical corporation is a VIE, and that we are the primary beneficiary as defined in the current accounting rules. Accordingly, we are required to consolidate the revenues and expenses of the managed medical corporation.


Management Services Agreements


Agreement

We have an executed MSA with a medical professional corporation and related treatment center, which continues on a month-to-month basis, unless terminated by cause.center. Under the MSA, we license to the treatment center the right to use our proprietary treatment programs and related trademarks and provide all required day-to-day business management services, including, but not limited to:


 ·

general administrative support services;

 ·

information systems;

 ·

recordkeeping;

 ·

scheduling;

 ·

billing and collection;

 ·

marketing and local business development; and

 ·

obtaining and maintaining all federal, state and local licenses, certifications and regulatory permits.


The treatment center retains the sole right and obligation to provide medical services to its patients and to make other medically related decisions, such as the choice of medical professionals to hire or medical equipment to acquire and the ordering of drugs.


In addition, we provide medical office space to the treatment center on a non-exclusive basis, and we are responsible for all costs associated with rent and utilities. The treatment center pays us a monthly fee equal to the aggregate amount of (a) our costs of providing management services (including reasonable overhead allocable to the delivery of our services and including salaries, rent, equipment, and tenant improvements incurred for the benefit of the medical group, provided that any capitalized costs will be amortized over a five yearfive-year period), (b) 10%-15% of the foregoing costs, and (c) any performance bonus amount, as determined by the treatment center at its sole discretion. The treatment center’s payment of our fee is subordinate to payment of the treatment center's obligations, including physician fees and medical group employee compensation.


We have also agreed to provide a credit facility to the treatment center to be available as a working capital loan, with interest at the prime ratePrime Rate plus 2%.  Funds are advanced pursuant to the terms of the MSA described above. The notes are due on demand or upon termination of the MSA. At March 31,September 30, 2013, there was one outstanding credit facility under which $12.5$12.9 million was outstanding. Our maximum exposure to loss could exceed this amount, and cannot be quantified as it is contingent upon the amount of losses incurred by the respective treatment center that we are required to fund under the credit facility.


Under the MSA, the equity owner of the affiliated treatment center has only a nominal equity investment at risk, and we absorb or receive a majority of the entity’s expected losses or expected residual returns. We also agree to provide working capital loans to allow for the treatment center to pay for its obligations. Substantially all of the activities of the managed medical corporation either involves us or are conducted for our benefit, as evidenced by the facts that (i) the operations of the managed medical corporation is conducted primarily using our licensed protocols and (ii) under the MSA, we agree to provide and perform all non-medical management and administrative services for the treatment center. Payment of our management fee is subordinate to payments of the obligations of the treatment center, and repayment of the working capital loans is not guaranteed by the equity owner of the affiliated treatment center or other third party. Creditors of the managed medical corporation do not have recourse to our general credit. Based on these facts, we have determined that the managed medical corporation is a VIE and that we are the primary beneficiary as defined in current accounting rules.  Accordingly, we are required to consolidate the assets, liabilities, revenues and expenses of the managed treatment center.

 

13


The amounts and classification of assets and liabilities of the VIE included in our condensed consolidated balance sheets at March 31,as of September 30, 2013 and December 31, 2012, are as follows:


(in thousands) 
March 31,
2013
  
(audited)
December 31,
2012
 
Cash and cash equivalents $9  $11 
Receivables, net  21   19 
Total assets $30   30 
         
Accounts payable  15   15 
Note payable to Catasys, Inc.  12,470   12,267 
Total liabilities $12,485   12,282 

(in thousands)

 

September 30,

2013

  

(audited)

December 31,

2012

 

Cash and cash equivalents

 $3  $11 

Receivables, net

  25   19 

Total assets

 $28   30 
         

Accounts payable

  13   15 

Note payable to Catasys, Inc.

  12,904   12,267 

Total liabilities

 $12,917   12,282 

Warrant Liabilities


In April 2013, we entered into the April Agreements with several investors relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock and warrants to purchase an aggregate of 2,192,857 shares of common stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1.5 million (the “April Offering”). The April Agreements provide that in the event that we effectuate a Reverse Split and the VWAP period declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that we shall issue the Adjustment Shares. We effectuated a reverse split on May 6, 2013, and no Adjustment Shares were issued.

The April Warrants expire in April 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our common stock, or other securities convertible into our common stock, for a per share price less than the exercise price of the April Warrants, the exercise price of the April Warrants will be reduced to such lower price, subject to customary exceptions. In the event that Adjustment Shares are issued, the number of shares that may be purchased under the April Warrants shall be increased by an amount equal to the Adjustment Shares. In addition, the exercise price is subject to adjustment in the event that the VWAP during the VWAP period is less than the exercise price prior to the VWAP Period.

We have issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.


For the three and nine months ended March 31,September 30, 2013, and 2012, we recognized a non-operating gain of $4.4$2.2 million and $37,000,$2.6 million, compared with a non-operating gain of $1.8 million and $4.1 million for the same periods in 2012, respectively, related to the revaluation of our warrant liabilities.


Recently Issued or Newly Adopted Accounting Standards


In December 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-11,Disclosures about Offsetting Assets and Liabilities(“ASU 2011-11”). The amendments in this update require enhanced disclosures around financial instruments and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The amendments are effective during interim and annual periods beginning after December 31, 2012. The adoption of ASU No. 2011-11 did not have a material effect on our consolidated financial statements or disclosures.

 

In February 2013, the FASB issued ASU 2013-02,Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220,Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.

14


In July 2013, the FASB issued ASU 2013-11,Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, (“ASU 2013-02”), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. We are evaluating the impact, if any, of the adoption of ASU 2013-11 on our balance sheet.

Note 3. Segment Information


We manage and report our operations through two business segments: healthcare services and license and management services. We evaluate segment performance based on total assets, revenue and income or loss before provision for income taxes. Our assets are included within each discrete reporting segment. In the event that any services are provided to one reporting segment by the other, the transactions are valued at the market price. No such services were provided during the three and nine months ended March 31,September 30, 2013 and 2012. Summary financial information for our two reportable segments are as follows:

(in thousands) 
Three Months Ended
March 31,
 
  2013  2012 
       
Healthcare services      
Revenues $99  $40 
Income/(loss) before provision for income taxes  2,862   (3,003)
Assets *  2,291   628 
         
License and management services        
Revenues $36  $53 
Loss before provision for income taxes  (247)  (377)
Assets *  1,042   2,007 
         
Consolidated continuing operations        
Revenues $135  $93 
Income/(loss) before provision for income taxes  2,615   (3,380)
Assets *  3,333   2,635 

 

(in thousands)

 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2013

  

2012

  

2013

  

2012

 
                 

Healthcare services

                

Revenues

 $109  $100  $315  $226 

Income (loss) before provision for income taxes

 $924  $66  $(2,441) $(4,714)

Assets *

  1,117   2,068   1,117   2,068 
                 

License and management services

                

Revenues

 $21  $40  $83  $136 

Loss before provision for income taxes

 $(242) $(321) $(735) $(1,157)

Assets *

  970   1,603   970   1,603 
                 

Consolidated continuing operations

                

Revenues

 $130  $140  $398  $362 

Income (loss) before provision for income taxes

 $682  $(255) $(3,176) $(5,871)

Assets *

  2,087   3,671   2,087   3,671 

* Assets are reported as of March 31.

September 30.

 

Healthcare Services


Catasys’s

Catasys’ integrated substance dependence solutions combine innovative medical and psychosocial treatments with elements of traditional disease management, case management and ongoing member support to help organizations treat and manage substance dependent populations to impact both the medical and behavioral health costs associated with substance dependence and the related co-morbidities.


We are currently marketing our integrated substance dependence solutions to managed care health plans on a case rate, or monthly fee basis, or fee-for-service basis, which involves educating third party payors on the disproportionately high cost of their substance dependent population and demonstrating the potential for improved clinical outcomes and reduced cost associated with using our Catasys programs. We haveare operating our programs in Kansas, Massachusetts, Louisiana, and Oklahoma. In March 2013, we signed an agreementtwo agreements with a national health planplans to provide services to their members in New Jersey which weand Kentucky, Ohio, West Virginia, and Indiana, respectively. We have launched enrollment in Kentucky and West Virginia in October 2013 and expect to commence enrollment duringin the secondremaining states by the end of the fourth quarter of 2013.


15

The following table summarizes the operating results for Healthcare Services for the three and nine months ended March 31,September 30, 2013 and 2012:


(in thousands) 
Three Months Ended
March 31,
 
  2013  2012 
       
Revenues $99  $40 
         
Operating Expenses        
Cost of healthcare services $144  $139 
General and administrative expenses        
Salaries and benefits  1,013   1,569 
Other expenses  435   749 
Depreciation and amortization  5   2 
Total operating expenses $1,597  $2,459 
         
Loss from operations $(1,498) $(2,419)
Interest expense  -   (621)
Change in fair value of warrant liabilities  4,360   37 
Income/(loss) before provision for income taxes $2,862  $(3,003)

(in thousands)

 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2013

  

2012

  

2013

  

2012

 
                 

Revenues

 $109  $100  $315  $226 
                 

Operating Expenses

                

Cost of healthcare services

 $162  $135  $454  $427 

General and administrative expenses

                

Salaries and benefits

  916   1,187   2,874   4,275 

Other expenses

  330   531   1,246   1,662 

Depreciation and amortization

  7   (2)  18   6 

Total operating expenses

 $1,415  $1,851  $4,592  $6,370 
                 

Loss from operations

 $(1,306) $(1,751) $(4,277) $(6,144)

Interest and other income

  -   -   -   - 

Interest expense

  (1)  (1)  (771)  (2,697)

Change in fair value of warrant liabilities

  2,231   1,818   2,607   4,127 

Income/(loss) before provision for income taxes

 $924  $66  $(2,441) $(4,714)
 

License and Management Services


Our license and management services segment licensesprimarily represents our proprietary treatment program to physicians. Also included in this segment is a licensed and managed treatment center,office, which offers a range of addiction treatment and mental health services.


The following table summarizes the operating results for License and Management Services for the three and nine months ended March 31,September 30, 2013 and 2012:

(In thousands)

 

Three months ended

September 30,

  

Nine months ended

September 30,

 
  

2013

  

2012

  

2013

  

2012

 

Revenues

                

U.S. licensees

 $-  $-  $6  $14 

Managed treatment center

  21   40   77   122 

Total license and management revenues

 $21  $40  $83  $136 
                 

Operating expenses

                

Cost of license and management services

 $59  $63  $174  $191 

General and administrative expenses

                

Salaries and benefits

  114   150   358   465 

Other expenses

  55   77   173   227 

Impairment losses

  -   -   -   189 

Depreciation and amortization

  35   71   113   221 

Total operating expenses

 $263  $361  $818  $1,293 
                 

Loss from operations

 $(242) $(321) $(735) $(1,157)

Interest and other income

  -   -   -   - 

Interest expense

  -   -   -   - 

Loss before provision for income taxes

 $(242) $(321) $(735) $(1,157)


(In thousands) 
Three Months Ended
March 31,
 
  2013  2012 
Revenues      
U.S. licensees $6  $8 
Managed treatment center  30   45 
Total license and management revenues $36  $53 
         
Operating expenses        
Cost of license and management services $60  $65 
General and administrative expenses        
Salaries and benefits  125   155 
Other expenses  57   97 
Impairment losses  -   34 
Depreciation and amortization  41   79 
Total operating expenses $283  $430 
         
Loss from operations $(247) $(377)
Interest and other income  -   - 
Interest expense  -   - 
Loss before provision for income taxes $(247) $(377)
16

Note 4. Receivable – Related Party


Disclosure

In December 2010, we entered into a three-year sublease agreement with Xoftek, Inc., an affiliate of our Chairman and CEO,Chief Executive Officer (“CEO”), to sublease approximately one-third of our office space for a three-year term for a monthly rent of approximately $11,000 per month. The related party receivable as of March 31,September 30, 2013 and December 31, 2012 was $205,000$269,000 and $173,000, respectively. We have received approximately $81,000 in payments through March 31,September 30, 2013.


Crede, an affiliate of our Chairman and CEO, and Shamus, an affiliate of the Company, participated in our April 2013 Offering. They received approximately 2,055,715 shares of common stock and warrants to purchase an aggregate 2,055,715 shares of common stock at a price of $0.70 per share, for gross proceeds of approximately $1.4 million.

Note 5. Restatement of Financial Statements


The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock split that occurred on May 6, 2013.


Note 6. Subsequent Events


In AprilOctober 2013, we entered into securities purchase agreements (the “Agreements”) with several investors, including Crede CG II,III, Ltd. (“Crede”Crede III”), an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and David Smith,Shamus, an affiliate of the Company, relating to the sale and issuance of an aggregate of 2,192,857 4,550,002 shares of common stock, and warrants (the “April“October Warrants”) to purchase an aggregate of 2,192,8574,550,002 shares of Common Stock at an exercise price of $0.70$0.58 per share for aggregate gross proceeds of approximately $1,535,000.$2.6 million. The AprilOctober Warrants expire in AprilOctober 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our Common Stock, or other security convertible into our Common Stock, for a per share price less than the exercise price of the AprilOctober Warrants, the exercise price of the AprilOctober Warrants will be reduced to such lower price, subject to customary exceptions.


Among other things, the Agreements provide that in the event that the Company effectuates a reverse stock split of its Common Stock within 24 months of the closing date of the Offering (the “Reverse Split”) and the volume weighted average price (“VWAP”) of the Common Stock during the 20 trading days following the effective date of the Reverse Split (the “VWAP Period”) declines from the closing price on the trading date immediately prior to the effective date of the Reverse Split, that the Company issue additional shares of Common Stock (the “Adjustment Shares"). The number of Adjustment Shares shall be calculated as the lesser of (a) 20% of the number of shares of Common Stock originally purchased by such investor and still held by the investor as of the last day of the VWAP Period, and (b) the number of shares originally purchased by such investor and still held by such investor as of the last day of the VWAP Period multiplied by the percentage decline in the VWAP during the VWAP Period. All prices and number of shares of Common Stock shall be adjusted for the Reverse Split and any other stock splits or stock dividends.

In November 2013, we signed an office lease for new corporate offices located in Los Angeles, California.


In May 2013, the Company effected a 10-for-1 reverse stock split.

17


Item 2.     Management's Discussion and Analysis of Financial Condition and Results of Operations


The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements andincluding the related notes, and the other financial information included in this report.


CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION


This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management, markets for stock of Catasys and other matters. Statements in this report that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act of 1934 and Section 27A of the Securities Act of 1933. Such forward-looking statements, including, without limitation, those relating to the future business prospects, our revenue and income, wherever they occur, are necessarily estimates reflecting the best judgment of our senior management onas of the date on which they were made, or if no date is stated, as of the date of this report. These forward-looking statements are subject to risks, uncertainties and assumptions, including those described in the “Risk Factors” in Item 1A of Part I of our most recent Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2012 and other reports we filed with the Securities and Exchange Commission (“SEC”), that may affect the operations, performance, development and results of our business. Because the factors discussed in this report could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We assume no obligation and do not intend to update these forward looking statements, except as required by law.


OVERVIEW


General


We are a healthcare services company, providing specialized health services designed to assist health plans employers and unionsother third party payors to manage and treat their high cost substance dependence members through a network of healthcare providers and our employees.  The OnTrak substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to improvelower costs by improving member health through the delivery of integrated medical and psychosocial interventions in combination with long term “care coaching” thereby lowering overall healthcare costs.  Catasyscoaching.”  We also offers the PROMETA Treatment Program for alcoholism and stimulant dependence on a private-pay basis through licensed treatment providers andhave a company managed treatment centerpsychiatry practice that offers a variety of mental health and substance dependence treatments primarily on a fee-for-service basis out of our offices and via telephonic psychiatry.

Operations

In the PROMETA Treatment Program, as well as other treatments for substance dependencies.


Operations

We have launchedthird quarter of 2013 we are operating our integrated substance dependence solutions for third-party payors in Kansas, Louisiana, Massachusetts, and Oklahoma. In March 2013, we signed a national agreement with a national health plan to provide the OnTrak program to their commercial members starting in New Jersey. In June 2013, we signed an agreement with a national health plan to provide services to their individually enrolled Medicare Advantage members in New Jersey, whichOhio, West Virginia, Kentucky, and Indiana. Implementation is under way and we have launched enrollment in Kentucky and West Virginia in October 2013 and we expect to commence enrollment duringin the secondremaining states by the end of the fourth quarter of 2013. However as our customers control significant portions of implementation, there are no assurances that commencement will not be delayed. Together these two contracts are expected to more than quadruple the number of members covered by our OnTrak programs.We believe that our Catasys offerings will address a high cost segment of the healthcare market for substance dependence, and we are currently marketing our Catasys integrated substance dependence solutions to managed care health plans on a case rate, or monthly fee or fee-for-service basis, which involves educating third party payors on the disproportionately high cost of their substance dependent population and demonstrating the potential for improved clinical outcomes and reduced cost associated with using our Catasys programs.


Under our licensing agreements, we provide physicians and other licensed treatment providers access to our proprietary treatment program, education and training in the implementation and use of the licensed technology. We receive a fee for the licensed technology and related services generally on a per patient basis. While we continue to maintain a small number of licensing agreements with physicians in the United States, we no longer provide any significant support or marketing related to the proprietary treatment program. Two of the Company’s sites contributed to revenue in the three months ended March 31, 2013. While we currently do not anticipate doing so, we may enter into agreements on a selective basis with additional healthcare providers.
18


We currently manage, under a licensing agreement, one professional medical corporation located in Los Angeles, California (dba The Center to Overcome Addiction).  We manage the business components of the professional medical corporation and license thea proprietary treatment program in exchange for management and licensing fees under the terms of full business service management agreements. The professional medical corporation offers medical and psychosocial interventions for substance dependencies and mental health disorders. The revenues and expenses of this center are included in our condensed consolidated financial statements under accounting standards applicable to variable interest entities. In July 2012, we moved the professional medical corporation offices into our corporate offices, which reduced operating expenses.expenses, and as of November 2013 the majority of services are being delivered telephonically.  We expect revenues associated with the treatment centers to continue to decline and are currently evaluating and considering additional actions to streamline our operations that may impact the managed treatment center.


RESULTS OF OPERATIONS


Table of Summary Consolidated Financial Information

The table below and the discussion that follows summarizesummarizes our results of consolidated operations for the three and nine months ended September 30, 2013 and 2012:

(In thousands, except per share amounts)

 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
  

2013

  

2012

  

2013

  

2012

 

Revenues

                

Healthcare services revenues

 $109  $100  $315  $226 

License and management services revenues

  21   40   83   136 

Total revenues

  130   140   398   362 
                 

Operating expenses

                

Cost of services

  221   197   628   618 

General and administrative

  1,415   1,946   4,651   6,629 

Impairment losses

  -   -   -   189 

Depreciation and amortization

  42   69   131   227 

Total operating expenses

  1,678   2,212   5,410   7,663 
                 

Loss from operations

  (1,548)  (2,072)  (5,012)  (7,301)
                 

Interest and other income

  -   -   -   - 

Interest expense

  (1)  (1)  (771)  (2,697)

Change in fair value of warrant liability

  2,231   1,818   2,607   4,127 

Income/(Loss) from operations before provision for income taxes

  682   (255)  (3,176)  (5,871)

Provision for income taxes

  2   2   5   18 

Net Income/(Loss)

 $680  $(257) $(3,181) $(5,889)
                 

Basic and diluted net income (loss) per share:*

                

Basic net income (loss) per share*

 $0.05  $(0.04) $(0.24) $(1.23)

Basic weighted number of shares outstanding*

  14,286   5,908   13,429   4,802 

Diluted net income (loss) per share*

 $0.04  $(0.04) $(0.24) $(1.23)

Diluted weighted number of shares outstanding*

  19,364   5,908   13,429   4,802 
 

*

The financial statements have been retroactively restated to reflect the 10-for-1 reverse stock splitthat occurred on May 6, 2013.

Summary of Consolidated Operating Results

We had a net income from continuing operations before provision for income taxes of $682,000 and a net loss of $257,000 for the three months ended March 31,September 30, 2013 and 2012:


(In thousands, except per share amounts) 
Three Months Ended
March 31,
 
  2013  2012 
Revenues      
Healthcare services revenues $99  $40 
License and management services revenues  36   53 
Total revenues $135  $93 
         
Operating expenses        
Cost of healthcare services $204  $204 
General and administrative  1,629   2,570 
Impairment losses  -   34 
Depreciation and amortization  47   81 
Total operating expenses $1,880  $2,889 
         
Loss from operations $(1,745) $(2,796)
         
Interest expense  -   (621)
Change in fair value of warrant liability  4,360   37 
Income/(Loss) from operations before provision for income taxes $2,615  $(3,380)
Provision for income taxes  2   (7)
Net Income/(Loss) $2,613  $(3,373)
         
Basic and diluted net income (loss) per share:*        
Basic net income (loss) per share* $0.22  $(0.99)
         
Basic weighted number of shares outstanding*  12,057   3,390 
         
Diluted net income (loss) per share* $0.16  $(0.99)
         
Diluted weighted number of shares outstanding*  16,562   3,390 
*2012, respectively. The financial statements have been retroactively restateddifference primarily relates to reflect the 10-for-1 reverse stock split that occurredincrease in the gain on May 6, 2013.
19

Three months ended March 31, 2013 compared with the three months ended March 31, 2012

fair value of warrants of $413,000 and the decrease in operating expense of $534,000. We had a $2.6$3.2 million net incomeand $5.9 million loss from continuous operationcontinuing operations before the provision for income taxes duringtax for the threenine months ended March 31,September 30, 2013 compared with a $3.4 millionand 2012. The reduction in net loss for the same period in 2012.  The difference is primarily duerelates to a $4.3 million gain in the change in fair value of the warrant liability, the decrease in operating expenses of $1.0$2.3 million, and the decrease inreduction of interest expense of $621,000 for$1.9 million, offset by a decrease in the period ended March 31,gain on the fair value of warrants of $1.5 million. 


Revenues

As of September 30, 2013, compared withfive healthcare services contracts were operational covering a significant increase in the number of patient’s being treated during the same period in 2012.


Revenues

In the three and nine months ended September 30, 2013, enrollment increased 133% and 82%, respectively, over the same periods in 2012. As of March 31, 2013, four health plan contracts were operational and an additional contract was signed in March 2013 which will become operational in the second quarter of 2013.  Recognizeda result, recognized revenue for our healthcare services segment increased by 148%9% and 39%, or $59,000,$9,000 and $89,000, for the three and nine months ended March 31,September 30, 2013, respectively, compared towith the same periodperiods in 2012.  MostIn addition, most of the revenueour fees related to these contracts are initially recorded to deferred revenue as the revenue isrevenues are subject to performance guarantees, or in thefor contracts on a case of case rate basis, recognized ratably over the period of enrollment. Deferred revenue was $316,000 at March 31,$667,000 and $278,000 as of September 30, 2013 and 2012, respectively, which ifreflects the increasing enrollment. If we were able to recognize this revenue, we would have increased healthcare services revenue to $415,000,by $478,000 for the nine months ended September 30, 2013, or 936%95%, compared with the same period in 2012.

Revenues decreased by $17,000$19,000 and $53,000 for the license and management services segment, for the three and nine months ended March 31,September 30, 2013, respectively, compared with the same periodperiods in 2012 due to a decrease in number of patient visits at the managed physician practice primarily related to the move of the treatment office as well as continuing to decrease resources allocated to the practice. We anticipate that revenue associated with this segment will continue to decrease as we continuedcontinue to focus on our healthcare services segment and reposition ourselves in the marketplace.


segment.

Cost of Healthcare Services


Cost of healthcare services consists primarily of salaries related to our care coaches, healthcare provider claims payments, and fees charged by our third party administratoradministrators for processing these claims.  CostThe increase of healthcare services remained flat$24,000 and $10,000 for the three and nine months ended March 31,September 30, 2013, compared with the same periodperiods in 2012, as we continuerelates primarily to service an increasing numberthe increase in members being treated, the mix in members treated, and the addition of enrolled members inmore care coaches to our Onstaff.

Trak program.


General and Administrative Expenses

General

Total general and administrative expenses amounted to $1.6expense decreased by $531,000 and $2.0 million for the three and nine months ended March 31,September 30, 2013, respectively, compared with $2.6 million for the same periodperiods in 2012. The decrease was due primarily due to a reduction in salaries and benefits and outside services.


share-based compensation expense as a result of a majority of our stock options becoming fully vested at the end of 2012.

Impairment Losses


We had no impairment losses during the first quarternine months of 2013 compared with $34,000$189,000 in impairment charges related to intellectual property for the same period in 2012.


There was no impairment lossesloss related to property plant and equipment for the three and nine months ended March 31,September 30, 2013 and 2012.


Interest Expense


Interest expense decreased by $621,000was flat for the three months ended March 31,September 30, 2013 and decreased by $1.9 million for the nine months ended September 30, 2013 compared with the same period in 20122013 due to interest recorded on a bridgethe conversion of note issued in February 2012 which was converted into common stockpayables to equity that occurred in April 2012.  There was no such bridge loan issued during the three months ended of 2013.


Change in fair value of warrant liability


We issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

 

20


The change in fair value of the warrants amounted to a net gain of $4.4increased by $413,000 and decreased by $1.5 million for the three and nine months ended March 31,September 30, 2013, respectively, compared with a net gain of $37,000 for the same periodperiods in 2012.


We will continue to mark the warrants to market value each quarter-end until they are completely settled.


LIQUIDITY AND CAPITAL RESOURCES


Liquidity and Going Concern


As of May 14,November 13, 2013, we had a balance of approximately $2.4$2.1 million cash on hand. We had working capital deficit of approximately $2.0$3.5 million at March 31,September 30, 2013. We have incurred significant net losses and negative operating cash flows since our inception. We could continue to incur negative cash flows and net losses for the next twelve months. Our current cash burn rate is approximately $450,000 per month, excluding non-current accrued liability payments. We expect our current cash resources to cover expenses at least into November 2013,the second quarter of 2014, however delays in cash collections, revenue, or unforeseen expenditures, could impact this estimate.  We may need to seek additional sources of capital prior to such time and there is no assurance that additional capital can be raised in an amount which is sufficient for us or on terms favorable to our stockholders, if at all.


In April 2013, we entered into securities purchase agreements with several investors, including Crede CG II, Ltd., an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and David Smith,Shamus, LLC, an affiliate of the Company, relating to the sale and issuance of an aggregate of 2,192,857 shares of common stock, and warrants (the “April Warrants”) to purchase an aggregate of 2,192,857 shares of Common Stock at an exercise price of $0.70 per share for aggregate gross proceeds of approximately $1,535,000. The April Warrants expire in April 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our Common Stock, or other security convertible into our Common Stock, for a per share price less than the exercise price of the April Warrants, the exercise price of the April Warrants will be reduced to such lower price, subject to customary exceptions.


In October 2013, we entered into securities purchase agreements with several investors, including Crede CG III, Ltd., an affiliate of Terren S. Peizer, Chairman and Chief Executive Officer of the Company, and Shamus LLC, an affiliate of the Company, relating to the sale and issuance of an aggregate of 4,550,002 shares of common stock, and warrants (the “October Warrants”) to purchase an aggregate of 4,550,002 shares of Common Stock at an exercise price of $0.58 per share for aggregate gross proceeds of approximately $2.6 million. The October Warrants expire in October 2018, and contain anti-dilution provisions. As a result, if we, in the future, issue or grant any rights to purchase any of our Common Stock, or other security convertible into our Common Stock, for a per share price less than the exercise price of the October Warrants, the exercise price of the October Warrants will be reduced to such lower price, subject to customary exceptions.

We have a related party receivable from Xoftek, Inc., an affiliate of Terren S. Peizer, our Chairman and Chief Executive Officer, in the amount of $205,000$269,000 at March 31,September 30, 2013, which represents unpaid monthly rent related to a January 1, 2011 sublease agreement.


Our ability to fund our ongoing operations and continue as a going concern is dependent on our increasing fees from existing contracts, successfully implementing and enrolling members under our two new contracts, and signing and generating fees from existing and newadditional contracts for our Catasys managed care programs and the success of management’s plans to increase revenue and continue to control expenses. We are currently operating our programs in Kansas, Kentucky, Louisiana, Oklahoma, Massachusetts, and Massachusetts.  West Virginia. In March 2013, we signed a national agreement with a national health plan to provide the OnTrak program to their commercial members starting in New Jersey. In June 2013, we signed an agreement with a national health plan to provide services to their individually enrolled Medicare Advantage members in New Jersey, whichOhio, West Virginia, Kentucky, and Indiana. Implementation is under way and we expect to commence enrollment duringfor both new contracts by the secondend of the fourth quarter of 2013. 2013, however as our customers control significant portions of implementation, there are no assurances that commencement will not be delayed. We have begun to generateare generating fees from the launched programs, we have increased fees during the first quarternine months of 2013 over the same period in the prior year, and we expect to continue to increase enrollment and fees from our programs throughout this year. However, there can be no assurance that we will generate such fees. In addition, we have continued to seek areas to reduce our operating expenses.

 

In addition, wewe and our Chief Executive Officer are party to a litigation in which the plaintiffs assert causes of action for conversion, a request for an order to set aside fraudulent conveyance and breach of contract. While we believe the plaintiffs’ claims are without merit and we intend to continue to vigorously defend the case, there can be no assurance that the litigation will be resolved in our favor. If this case is decided against us or our Chief Executive Officer, it may cause us to pay substantial damages, and other related fees. Regardless of whether this litigation is resolved in our favor, any lawsuit to which we are a party will likely be expensive and time consuming to defend or resolve. Costs of defense and any damages resulting from litigation, a ruling against us or a settlement of the litigation could have a significant negative impact on our liquidity, including our cash flows.

21


Cash Flows


We used $1.6$4.3 million of cash for continuing operating activities during the threenine months ended March 31,September 30, 2013 compared with $1.4$4.5 million during the same period in 2012. Significant non-cash adjustments to operating activities for the threenine months ended March 31,September 30, 2013 included share-based compensation expense of $68,000,$165,000, depreciation and amortization of $47,000, offset by$131,000, amortization of debt discount of $769,000, and a fair value adjustment on warrant liability of $4.3$2.6 million.


Capital expenditures for the threenine months ended March 31,September 30, 2013 were not material. Our future capital expenditure requirements will depend upon many factors, including progress with our marketing efforts, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.


Our net cash provided by financing activities was $20,000$1.5 million for the threenine months ended March 31,September 30, 2013, compared with net cash provided by financing activities of $773,000$5.3 million for the threenine months ended March 31,September 30, 2012. Cash provided by financing activities for the threenine months ended March 31,September 30, 2013 consisted primarily of the proceeds from the exercise of warrants during the first quarter of 2013 and the net proceeds from the securities offerings in April 2013, leaving a balance of $1.6 million$422,000 in cash and cash equivalents at March 31,September 30, 2013.


OFF BALANCE SHEET ARRANGEMENTS


As of March 31,September 30, 2013, we had no off-balance sheet arrangements.


CRITICAL ACCOUNTING ESTIMATES


The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.


We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates and the nature of our related disclosures herein with the audit committee of our Board of Directors. We believe our accounting policies specific to the fair value of warrants, share-based compensation expense, and the impairment assessment for intangible assets, involve our most significant judgments and estimates that are material to our condensed consolidated financial statements. They are discussed further below.


Warrant Liabilities

We issued warrants to purchase common stock in July 2010, October 2010, November 2010, December 2011, February 2012, April 2012, May 2012, September 2012, December 2012, April 2013, and when we amended and restated the Highbridge senior secured note in July 2008. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control.  The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.


For the three and nine months ended March 31,September 30, 2013, and 2012, we recognized a non-operating gain of $4.4$2.2 million and $37,000, respectively,$2.6 million, compared with a non-operating gain of $1.8 million and $4.1 million for the same period in 2012, related to the revaluation of our warrant liabilities.

22


Share-based compensation expense


We account for the issuance of stock, stock options, and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model’s calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.


The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based compensation expense from the amounts reported. Based on the 2012 assumptions used for the Black-Scholes pricing model, a 50% increase in stock price volatility would have increased the fair values of options by approximately 25%. The weighted average expected option term for the three and nine months ended March 31,September 30, 2013, reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.


From time to time, we have retained terminated employees as part-time consultants upon their resignation from ourthe Company. Because the employees continued to provide services to us, their options continued to vest in accordance with the original terms. Due to the change in classification of the option awards, the options were considered modified at the date of termination. The modifications were treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options were no longer accounted for as employee awards and were accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the three and nine months ended March 31,September 30, 2013.


Impairment of Intangible Assets


We have capitalized significant costs for acquiring patents and other intellectual property directly related to our products and services. We review our intangible assets for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In reviewing for impairment, we compare the carrying value of such assets to the estimated undiscounted future cash flows expected from the use of the assets and/or their eventual disposition. If the estimated undiscounted future cash flows are less than their carrying amount, we record an impairment loss to recognize a loss for the difference between the assets’ fair value and their carrying value. Since we have not recognized significant revenue to date, our estimates of future revenue may not be realized and the net realizable value of our capitalized costs of intellectual property or other intangible assets may become impaired.


During the three and nine months ended March 31,September 30, 2013, we did not acquire any new intangible assets and at March 31,as of September 30, 2013, all of our intangible assets consisted of intellectual property, which is not subject to renewal or extension. As of March 31, 2013 weWe had no intangible impairment. As of March 31,impairment for the three and nine months ended September 30, 2013. We had no intangible impairment for the three months ended September 30, 2012 we determined thatand $189,000 for the remaining lives of certain intangibles exceeded their economic useful lives and therefore accelerated amortization and recorded an impairment of $34,000.nine months ended September 30, 2012


Additionally, it is important to note that our overall business model, business operations and future prospects of our business have not changed materially since we performed the reviews and analysis noted above, with the exception of the timing and annualized amounts of expected revenue.


RECENT ACCOUNTING PRONOUNCEMENTS


In December 2011, the FASB issued Accounting Standards Update (“ASU”) No. 2011-11,Disclosures about Offsetting Assets and Liabilities(“ASU 2011-11”). The amendments in this update require enhanced disclosures around financial instruments and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The amendments are effective during interim and annual periods beginning after December 31, 2012. The adoption of ASU No. 2011-11 did not have a material effect on our consolidated financial statements or disclosures.

23

In February 2013, the FASB issued ASU 2013-02,Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, (“ASU 2013-02”). ASU 2013-02 amends ASC 220,Comprehensive Income (“ASC 220”), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on our consolidated financial position or results of operations.


In July 2013, the FASB issued ASU 2013-11,Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, (“ASU 2013-02”), which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. We are evaluating the impact, if any, of the adoption of ASU 2013-11 on our balance sheet.

Item 3.     Quantitative and Qualitative Disclosures About Market Risk


Not applicable.


Item 4.     Controls and Procedures


Disclosure Controls


We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31,September 30, 2013. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.


Changes in Internal Control Over Financial Reporting


There were no changes in our internal controls over financial reporting during the three months ended March 31,September 30, 2013, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

24

PART II – OTHER INFORMATION


Item 1.     Legal Proceedings

On or about August 18, 2006, plaintiffs Isaka Investments, Ltd., Sand Hill Capital International Inc. and Richbourg Financial, Ltd. (“Plaintiffs”) filed a complaint in the Los Angeles Superior Court, entitledIsaka Investments, Ltd., Sand Hill Capital International, Inc. and Richbourg Financial, Ltd. vs. Xino Corporation, an entity from which ourthe Company had acquired certain assets, and a number of other additional individuals and entities, including ourthe Company, ourthe Company’s Chairman and Chief Executive Officer, Terren S. Peizer, and other members of the Company’s Board of Directors. The Board of Directors and other parties were dismissed by way of demurrer. In July 2007, Plaintiffs filed their second amended complaint, asserting causes of action for conversion, a request for an order to set aside an alleged fraudulent conveyance and breach of contract against ourthe Company, Mr. Peizer, and others. In August 2007, ourthe Company and Mr. Peizer, among others, filed an answer to the second amended complaint denying liability and asserting numerous affirmative defenses. In June 2008, ourthe Company, Mr. Peizer, and others, filed a motion for summary judgment, or alternatively, summary adjudication, and in October 2008, the Court granted summary adjudication as to each cause of action and consequently summary judgment in favor of ourthe Company and Mr. Peizer, among others. Plaintiffs appealed the summary judgment and in October 2010, the Court of Appeal reversed the trial court’s ruling. The Court of Appeal’s decision was not on the merits, but rather provides that there are sufficient material issues of fact for the case to be tried. The Court of Appeal issued a remittitur in December 2010, and Plaintiffs filed a motion for leave to amend the second amended complaint, which was granted in June 2011. In June 2011, Plaintiffs filed their third amended complaint and, in August 2011, in response to a demurrer filed by the Company, Mr. Peizer and others, the Court held that Plaintiffs' third amended complaint was not pled with sufficient specificity to state the causes of action alleged therein. In September 2011, Plaintiffs filed a fourth amended complaint, alleging causes of action for breach of fiduciary duty, fraudulent transfer, conversion, fraud, breach of contract, unfair business practices and wrongful interference with contractual relations and prospective business advantage. The Company filed a demurrer related to the fourth amended complaint in September 2011. At the hearing, the Court sustained, without leave to amend, the demurrers to the causes of action for breach of fiduciary duty and wrongful interference with contractual relations and prospective business advantage. In October 2011, the Company, Mr. Peizer and others, filed an answer to the fourth amended complaint, denying liability and asserting numerous affirmative defenses. In April 2012, the Court conducted a bench trial on the issue of whether the Plaintiffs have standing to pursue the causes of action alleged in their Fourth Amended Complaint other than the causes of action for conversion and breach of contract. At the conclusion of the trial, the Court ruled that Plaintiffs lack standing to pursue any causes of action other than for conversion and breach of contract. A Statement of Decision and Order of Dismissal was signed by the Court on July 18, 2012. Thereafter, the Plaintiffs filed an ex parte application to reopen the evidence which was denied by the Court. The Plaintiffs also filed a motion to amend their complaint seeking to add back in the claims that they lost at trial. The motion to amend was denied. On July 3, 2012, September 5, 2012 and October 15, 2012, the Plaintiffs filed Petitions for Writs of Mandate in the Court of Appeal. The Writs were summarily denied by the Court of Appeal. On October 9, 2012, the Court commenced hearings regarding the trial of the conversion and breach of contract causes of action. On October 15, 2012, the parties, through their counsel of record, stipulated to a bench trial on the admissibility and enforceability of a 2007 settlement agreement between Xino Corporation and the Company (the "Settlement Agreement"). Thus, the parties submitted the issue to the Court for a bench trial to determine whether the Settlement Agreement was admissible and effective to bar the two remaining claims. The Court held that the Settlement Agreement was admissible and enforceable to release the remaining claims. Accordingly, judgment was entered for the Company on November 19, 2012. Plaintiffs filed a notice of appeal on December 10, 2012. On March 26, 2013, Plaintiffs filed their opening brief in the Court of Appeal.The Company’s response will be due on May 20,appeal has been fully briefed and an oral argument has been scheduled for December 11, 2013. The Company has had very limited settlement discussions and the Company believes Plaintiffs’ claims are without merit and intends to continuously, and vigorously, defend the case.


Item 1A.     Risk Factors

There have been no material changes in our risk factors from those disclosed in our most recent Annual Report on Form 10-K.

25


Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

None.


None.

Item 3.     Defaults Upon Senior Securities


None.


Item 4.     Mine Safety Disclosures.


Not applicable


applicable.

Item 5.     Other Information


None.

In November 2013, we signed an office lease for new corporate offices located in Los Angeles, California.

Item 6.     Exhibits


Exhibit 31.110.1Office Lease between Catasys, Inc. and Trizec Wilshire Center, LLC, dated November 6, 2013.

Exhibit 31.1

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 101@The following materials from Catasys, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Operations, (iii) the unaudited Condensed Consolidated Statements of Cash Flows, and (iv) the Notes to Condensed Consolidated Financial Statements, tagged as blocks of text.
101.INS**

101.INS

XBRL Instance

101.SCH**

101.SCH

XBRL Taxonomy Extension Schema

101.CAL**

101.CAL

XBRL Taxonomy Extension Calculation

101.DEF**

101.DEF

XBRL Taxonomy Extension Definition

101.LAB**

101.LAB

XBRL Taxonomy Extension Labels

101.PRE**

101.PRE

XBRL Taxonomy Extension Presentation

 
@Users of the XBRL data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities  Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

26


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


CATASYS, INC.

Date:   November 13, 2013

By:  

/s/ TERREN S. PEIZER  

Terren S. Peizer 

Chief Executive Officer

(Principal Executive Officer) 

 CATASYS, INC.

Date:   November 13, 2013

By:  

/s/ SUSAN ETZEL

Susan Etzel

Chief Financial Officer

(Principal Financial and Accounting Officer) 

  
  
Date:   May 15,  2013By:  /s/ TERREN S. PEIZER  
Terren S. Peizer 
Chief Executive Officer
(Principal Executive Officer) 
 
Date:   May 15,  2013By:  /s/ SUSAN ETZEL
Susan Etzel
Chief Financial Officer
(Principal Financial and Accounting Officer) 
27